CureVac

CureVac

A biopharmaceutical company developing prophylactic and therapeutic application of messenger RNA, which can be used to develop vaccines. It was founded in 2000 and is located in Tübingen, Germany.

CureVac is a Germany-based biopharmaceutical company specializing in designing technology that utilizes messenger RNA (mRNA) as a data carrier which is capable of instructing the human body to create proteins to fight viruses, such as COVID-19. The company's technology has been used in multiple medical contexts such as cancer and rare diseases.

Product

The company has both an mRNA platform and production capabilities. Its platform analyzes millions of naturally occurring sequences and houses a nucleotide sequence library where data can be utilized by the CureVac team to created a customized mRNA therapy. The company works in partnerships with other biotechnology entities, such as Lilly, CEPI, and the Bill and Melinda Gates Foundation, to operate its pipeline taking therapeutics from a pre-clinical discovery phase through Phase 2 of clinical trials before finally producing the medical product.

CureVac also produces its mRNA therapies in its own facilities. The company has Good Manufacturing Practices (GMP) and its facilities are capable of producing standardized therapeutics. Industrial manufacturing of products is possible and could be used to produce a vaccine for COVID-19, pending clinical trials.

Timeline

February 2, 2021
CureVac raises a $450,000,000 venture round.
September 15, 2020
CureVac raises a $306,000,000 grant.
July 21, 2020
CureVac raises a $126,000,000 venture round from Qatar Investment Authority.
July 20, 2020
CureVac raises a $183,000,000 corporate funding round from GlaxoSmithKline.
June 15, 2020
CureVac raises a $458,800,000 venture round from KfW.
November 3, 2015
CureVac raises a $29,500,000 series F round from Baillie Gifford and Sigma Capital Group.
November 3, 2015
CureVac raises a $119,633,000 series F round from Baillie Gifford, Bill & Melinda Gates Foundation, Sigma Group and dievini Hopp Biotech Holding.
March 5, 2015
CureVac raises a $76,000,000 series E round from Bill & Melinda Gates Foundation.
September 18, 2012
CureVac raises a $104,432,000 series D round from dievini Hopp Biotech Holding.
May 10, 2010
CureVac raises a $34,900,000 series C round from dievini Hopp Biotech Holding.
Page 1 of 2

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
CureVac Series F round
29,500,000
November 3, 2015
11 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Baron Jean Stéphenne

Supervisory Board

Bernd Winterhalter

Interim Chief Development Officer

Christopher Karp

Scientific Advisory Board

Craig A. Tooman

Supervisory Board

Daniel Speiser

Scientific Advisory Board

Dirk Jäger

Scientific Advisory Board

Florian von der Mülbe

Chief Production Officer and Co-Founder

Franz-Werner Haas

Chief Operating Officer

Fred Zepp

Scientific Advisory Board

Friedrich von Bohlen und Halbach

Supervisory Board

George R. Siber

Scientific Advisory Board

Gerd Zettlmeissl

Scientific Advisory Board

Hans-Georg Rammensee

Scientific Advisory Board

Ingmar Hoerr

Founder, Chairman of the Executive Board and Chief Executive Officer

Jean-Paul Prieels

Scientific Advisory Board

Karim Fizazi

Scientific Advisory Board

Mariola Fotin-Mleczek

Chief Technology Officer

Mathias Hothum

Supervisory Board

Michael P. Manns

Scientific Advisory Board

Michel De Wilde

Scientific Advisory Board

Nina Bhardwaj

Scientific Advisory Board

Pierre Kemula

Chief Financial Officer

Ralf Clemens

Supervisory Board & Chairman of the Scientific Advisory Board

Stanley Plotkin

Scientific Advisory Board

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

CureVac Receives €80M from EU to Fund Coronavirus Vaccine Amid US Dispute

Jonathan Smith

Web

March 17, 2020

Germany's CureVac Says Low-Dose Coronavirus Vaccine Could Allow for Mass Production

Reuters

Web

March 13, 2020

Documentaries, videos and podcasts

Title
Date
Link

About CureVac

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
April 10, 2021
mint
Curevac says it is already very advanced in phase three clinical trials and is expecting the data for the final approval package
BioSpace
March 23, 2021
BioSpace
First challenge infection study in preclinical mouse model to provide evidence for protection against SARS-CoV-2 variant CVnCoV induces robust antibody titers with virus variant neutralizing capacity in immunized animals
Angus Liu
March 24, 2021
FierceBiotech
Emerging coronavirus variants threaten the potency of existing COVID-19 vaccines, sending their manufacturers on a quest to develop booster shots. CureVac, which is in late-stage testing of its mRNA shot, now has mouse data showing its product could stave off one aggressive COVID-19 variant first identified in South Africa.
Julia Kollewe
March 6, 2021
the Guardian
The companies in line for the biggest windfalls - and the shareholders who have already made fortunes
Julia Kollewe
March 6, 2021
the Guardian
The companies in line for the biggest windfalls - and the shareholders who have already made fortunes
Amirah Al Idrus
February 5, 2021
FierceBiotech
On the heels of COVID-19 pacts with Bayer and GlaxoSmithKline, CureVac is joining forces with the U.K. government to tackle the next challenge--new variants of the SARS-CoV-2 virus. If approved, any vaccines that come out of the deal will be distributed in the U.K. and its overseas and dependent territories.
Beth Mole
February 3, 2021
Ars Technica
GSK, Sanofi, Novartis step up to help boost global COVID-vaccine supply.
Mark Sweney and Julia Kollewe
February 3, 2021
the Guardian
GlaxoSmithKline will also support CureVac manufacture up to 100m doses of the first-generation Covid-19 vaccine candidate, CVnCoV, this year. Photograph: Hollandse Hoogte/Rex/Shutterstock
Dr. Catherine Schuster-Bruce
February 3, 2021
Business Insider
The new GSK-CureVac mRNA vaccines will target coronavirus variants and could be available in 2022, if approved.
Ben Adams
January 13, 2021
FierceBiotech
German biotech CureVac shouldn't be discounted from being a major COVID-19 vaccine player despite being at the tail end of the race to market.
Ben Adams
January 13, 2021
FierceBiotech
Welcome to Day 3 of the annual J.P. Morgan healthcare conference. Here's your need to know, as Bayer says CureVac is not just an also-ran in the mRNA COVID-19 vaccine race while Aridis' CEO says the pandemic has lamentably not secured more interest in antibiotic R&D.
The Associated Press
January 7, 2021
Coronavirus
A German company that is in the advanced stages of producing a vaccine against COVID-19 is linking up with pharmaceutical giant Bayer to help develop and distribute the product.
Andrew Dunn
January 6, 2021
Business Insider
The world will need multiple effective coronavirus vaccines to combat this pandemic. Here's the latest news on the frontrunners.
Nick Paul
December 14, 2020
FierceBiotech
CureVac has begun a phase 2b/3 clinical trial of its COVID-19 vaccine candidate CVnCoV. The study will enroll 36,500 participants in Europe and Latin America with a view to generating data to support approval of the mRNA vaccine next year.
BioSpace
December 4, 2020
BioSpace
CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid announced today that Antony Blanc, PhD, was appointed Chief Business Officer and Chief Commercial Officer of CureVac.
By The Associated Press
November 23, 2020
AP NEWS
HELENA, Mont. -- The Montana governor's office says more than 100 contracted medical staff have arrived in the state to assist hospitals in responding to the spike in COVID-19 cases. The 110...
November 23, 2020
WebWire
CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Wacker Chemie AG announced today that they had signed a contract for the manufacturing of CureVac's COVID-19 vaccine candidate CVnCoV. Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 202...
Reuters
November 12, 2020
@bsindia
Haas told a news conference of foreign journalists that the company aimed to initiate rolling review of its vaccine in the first quarter of 2021
Nick Paul
November 10, 2020
FierceBiotech
CureVac has presented more clinical data on its COVID-19 vaccine candidate. The results strengthen the impression that the vaccine triggers potentially protective immune responses while leaving scope to question whether CureVac can clear the bar set by its more advanced rivals.
IANS
August 21, 2020
@bsindia
The company received earlier EU funding. In early July, the European Investment Bank and CureVac signed a 75-million-euro loan agreement for the development and large-scale production of vaccines
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.